WebMD Global requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.

Faculty

Allen P. Kaplan, MD

Clinical Professor of Medicine
Department of Medicine
Medical University of South Carolina
Charleston, South Carolina, United States

Disclosures

Allen P. Kaplan, MD, has no relevant financial relationships.

Marcus Maurer, MD

Marcus Maurer, MD
Professor of Dermatological Allergology
Institute of Allergology, Charité
Fraunhofer Institute of Translational Medicine and Pharmacology
Berlin, Germany

Disclosures

Marcus Maurer, MD, has the following relevant financial relationships:
Consultant or advisor for: Allakos; Amgen; Argenx; AstraZeneca; BioCryst; Blueprint; Celldex Therapeutics; CSL Behring; Dyax; Eli Lilly and Company; FAES; Genentech; GI Innovation; KalVista Pharmaceuticals; Kyowa Kirin; Leo Pharma; Menarini; Moxie; Novartis; Pharming; Pharvaris; Regeneron; Roche; Sanofi; Shire; Takeda; Third Harmonic Bio; UCB, Inc.; Uriach
Speaker or member of speakers bureau for: BioCryst; Celldex Therapeutics; CSL Behring; FAES; Menarini; Novartis; Regeneron; Sanofi; Shire; Takeda; Uriach
Research funding from: Allakos; Amgen; ArgenX; AstraZeneca; BioCryst; Blueprint; Celldex; CSL Behring; Dyax; Eli Lilly and Company; FAES; Genentech; GI Innovation; KalVista Pharmaceuticals; Kyowa Kirin; Leo Pharma; Menarini; Moxie; Novartis; Pharming; Pharvaris; Regeneron; Roche; Sanofi; Shire; Takeda; Third Harmonic Bio; UCB, Inc.; Uriach
Contracted researcher for: ArgenX; AstraZeneca; BioCryst; Blueprint; Celldex; CSL Behring; Dyax; Eli Lilly and Company; FAES; Genentech; GI Innovation; KalVista Pharmaceuticals; Kyowa Kirin; Leo Pharma; Menarini; Moxie; Novartis; Pharming; Pharvaris; Regeneron; Roche; Sanofi; Shire; Takeda; Third Harmonic Bio; UCB, Inc.; Uriach

Heike Röckmann, MD, PhD

Department of Dermatology/Allergology
University Medical Center Utrecht
Utrecht University
Utrecht, the Netherlands

Disclosures

Heike Röckmann, MD, PhD, has no relevant financial relationships.

Mark G. Lebwohl, MD

Professor and Waldman Chair
Department of Dermatology
Icahn School of Medicine at Mount Sinai
New York, New York, United States

Disclosures

Mark G. Lebwohl, MD, has the following relevant financial relationships:
Consultant or advisor for:
Research funding from: AbbVie; Amgen; Arcutis; Avotres Therapeutics; Boehringer Ingelheim; Cara Therapeutics; Dermavant Sciences; Incyte; Inozyme Pharma; Janssen Research & Development, LLC; Lilly; Novartis; Ortho Dermatologics; Regeneron; UCB, Inc.

Editors

Marinella Calle, PhD, CMPP

Medical Education Director, WebMD Global, LLC

Disclosures

Marinella Calle, PhD, CMPP, has no relevant financial relationships.

Chii Shyang Fong, PhD

Scientific Content Manager, WebMD Global, LLC

Disclosures

Chii Shyang Fong, PhD, has no relevant financial relationships.

Compliance Reviewer

Yaisanet Oyola, MD

Associate Director, Accreditation and Compliance

Disclosures

Yaisanet Oyola, MD, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.

From Medscape Education

Urticaria in Minutes: Key Topics in the Diagnosis, Assessment, and Management of Chronic Spontaneous Urticaria

Authors: Allen P. Kaplan, MD; Marcus Maurer, MD; Heike Röckmann, MD, PhD; Mark G. Lebwohl, MDFaculty and Disclosures

processing....

Posted: 28/11/2022

This activity is intended for dermatologists, allergists and clinical immunologists, and primary care physicians.

The goal of this activity is for learners to be better able to identify best practices for assessment and management of chronic spontaneous urticaria (CSU) as well as emerging therapies.

Upon completion of this activity, participants will be able to:

Have increased knowledge regarding the
- Assessment of CSU
- Clinical evidence on the use of biologic therapies
- Emerging therapies for the management of CSU

Contents of This Activity

Urticaria in Minutes: Key Topics in the Diagnosis, Assessment, and Management of Chronic Spontaneous Urticaria

Dr Kaplan lays out the program overview.
Allen P. Kaplan, MD

Best Practices for Diagnosis of Chronic Spontaneous Urticaria

Dr Kaplan discusses key symptoms of CSU and the complexity of CSU diagnosis.
Allen P. Kaplan, MD

Best Practices for Disease Assessment in Chronic Spontaneous Urticaria

Dr Maurer shares key tools used in assessing CSU disease activity, disease control and quality of life.
Marcus Maurer, MD

Guideline Recommendations for the Management of Chronic Spontaneous Urticaria

Dr Maurer and Dr Röckmann provide expert insights into the latest treatment guidelines for CSU.
Marcus Maurer, MD; Heike Röckmann, MD, PhD

Emerging Therapies in Chronic Spontaneous Urticaria

Dr Lebwohl presents new classes of drugs currently in clinical development for the treatment of CSU.
Mark G. Lebwohl, MD

Educational Impact Challenge

The goal of this activity is for learners to be better able to identify best practices for assessment and management of CSU as well as emerging therapies.

Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.

Page 1 of 11

Download Slides

Activity Transcript

Print
Like Tweet

Activity Transcript

Disclaimer

The educational activity presented above may involve simulated case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient is intended or should be inferred.

The material presented here does not necessarily reflect the views of WebMD Global, LLC or companies that support educational programming on medscape.org. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.

Faculty and Disclosures

Faculty

Allen P. Kaplan, MD

Marcus Maurer, MD

Heike Röckmann, MD, PhD

Mark G. Lebwohl, MD

Editors

Marinella Calle, PhD, CMPP

Chii Shyang Fong, PhD

Compliance Reviewer

Yaisanet Oyola, MD

Peer Reviewer

Urticaria in Minutes: Key Topics in the Diagnosis, Assessment, and Management of Chronic Spontaneous Urticaria

Contents of This Activity

Urticaria in Minutes: Key Topics in the Diagnosis, Assessment, and Management of Chronic Spontaneous Urticaria

Best Practices for Diagnosis of Chronic Spontaneous Urticaria

Best Practices for Disease Assessment in Chronic Spontaneous Urticaria

Guideline Recommendations for the Management of Chronic Spontaneous Urticaria

Emerging Therapies in Chronic Spontaneous Urticaria

Educational Impact Challenge